Vanda Pharmaceuticals (VNDA) rose nearly 8% in premarket trading as investors await an FDA decision due December 30 on Tradipitant, a motion-sickness drug licensed from Eli Lilly. The treatment is also being studied for gastroparesis. Vanda recently reported positive trial results showing Tradipitant reduced Wegovy-related nausea and vomiting in overweight and obese adults.